Video & Transcript DataContr Research : 'S331'
US
Us Congress 2025-2026 Regular Session
Business meeting to consider S.331, to amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and the nomination of Kashyap Patel, of Nevada, to be Director of the Federal Bureau of Investigation, Departmen Feb 13th, 2025 at 08:00 am
Senate Judiciary Committee
Bills:
SB331
Keywords:
fentanyl, controlled substances, drug trafficking, public health, research regulations, law enforcement, Kash Patel, FBI director nomination, S331, Fentanyl Act, committee meeting, legislative discussion
Summary:
In this committee meeting, the primary focus was on the nomination of Kash Patel for the position of director of the FBI, which had sparked considerable debate over the past week. Members discussed the extensive vetting process Patel underwent, including a lengthy hearing where he addressed numerous questions, which emphasized his qualifications and the support he received from various law enforcement organizations. The meeting included significant arguments from both sides, reflecting the polarized nature of the nomination, especially regarding the allegations made against Patel by some committee members. As discussions continued, the committee decided to hold off on the Fentanyl Act, listed as S331, until the next meeting, indicating a prioritization of the nomination vote over new legislative measures at this time.